Connect Biopharma 

$0.8022
26
-$0.03-3.97%Friday 20:00
-$0.01-1.52%Friday 22:56After hours

Statistics

Day High
0.8041
Day Low
0.7939
52W High
3.82
52W Low
0.732
Volume
9,928
Avg. Volume
-
Mkt Cap
50.52M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 18Expected
Q2 2023
Q1 2024
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.08
-0.79
-0.51
-0.22
Expected EPS
-0.26620924747
Actual EPS
N/A

Financials

-86,687.5%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
64,000Revenue
-55.48MNet Income

Analyst Ratings

$5.17Average Price Target
The highest estimate is ⁦7.00⁩.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CNTB. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie competes in the biopharmaceutical space, focusing on immunology and inflammatory diseases, similar to Connect Biopharma's focus.
AMGEN
AMGN
Mkt Cap217.9B
Amgen operates in the biotech industry, developing treatments for inflammatory diseases, directly competing with Connect Biopharma's product pipeline.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is involved in the discovery, development, and commercialization of medicines in areas including inflammatory and respiratory diseases, competing with Connect Biopharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals focuses on developing treatments for rheumatoid arthritis and asthma, areas that overlap with Connect Biopharma's therapeutic focus.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb offers a range of biopharmaceutical products targeting immune-mediated inflammatory disorders, competing with Connect Biopharma's research and development efforts.
Novartis
NVS
Mkt Cap268B
Novartis AG engages in the research, development, and marketing of healthcare products, including treatments for autoimmune diseases, making it a competitor.
Pfizer
PFE
Mkt Cap158.45B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, directly competing with Connect Biopharma.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG focuses on biotechnology products for various diseases, including inflammatory and autoimmune diseases, competing in the same space as Connect Biopharma.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for autoimmune diseases, making it a competitor in the biopharmaceutical field.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca operates in the biopharmaceutical sector, focusing on respiratory, cardiovascular, and autoimmune diseases, areas that overlap with Connect Biopharma's interests.

About

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Show More
CEO
Barry D. Quart
Employees
64
Country
Cayman Islands
ISIN
KYG235491019

Listings

0 Comments

Share your thoughts

FAQs

What is Connect Biopharma stock price today?▼
The current price of CNTB is $0.80 USD — it has decreased by -3.97% in the past 24 hours. Watch Connect Biopharma stock price performance more closely on the chart.
What is Connect Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Connect Biopharma stocks are traded under the ticker CNTB.
Is Connect Biopharma stock price growing?▼
CNTB stock has fallen by -5.5% compared to the previous week, the month change is a -13.46% fall, over the last year Connect Biopharma has showed a -53.09% decrease.
What is Connect Biopharma market cap?▼
Today Connect Biopharma has the market capitalization of 50.52M
When is the next Connect Biopharma earnings date?▼
Connect Biopharma is going to release the next earnings report on November 18, 2026.
What were Connect Biopharma earnings last quarter?▼
CNTB earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.31 USD resulting in a +14.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Connect Biopharma revenue for the last year?▼
Connect Biopharma revenue for the last year amounts to 64,000 USD.
What is Connect Biopharma net income for the last year?▼
CNTB net income for the last year is -55.48M USD.
How many employees does Connect Biopharma have?▼
As of November 2, 2026, the company has 64 employees.
In which sector is Connect Biopharma located?▼
Connect Biopharma operates in the Health & Wellness sector.
When did Connect Biopharma complete a stock split?▼
Connect Biopharma has not had any recent stock splits.
Where is Connect Biopharma headquartered?▼
Connect Biopharma is headquartered in SAN DIEGO, Cayman Islands.